Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 40.00
Ask: 43.00
Change: 0.50 (1.22%)
Spread: 3.00 (7.50%)
Open: 41.50
High: 41.50
Low: 41.50
Prev. Close: 41.00
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Portfolio news: Alusid launches luxury Block range

9 Apr 2020 07:00

RNS Number : 2831J
Frontier IP Group plc
09 April 2020
 

RNS REACH

AIM: FIPP

09 April 2020

 

Frontier IP Group plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Alusid launches luxury Block range through exclusive Kickstarter campaign

 

 

Frontier IP, a specialist in commercialising intellectual property, announces that portfolio company Alusid Limited ("Alusid" or the "Company") has launched a new luxury brand called Block via an exclusive Kickstarter campaign in collaboration with design consultancy Collective HQ.

 

Block, which has been named as a "Project We Love" by the Kickstarter team, demonstrates the ability of Alusid to create beautiful, premium-quality, hand-crafted solid surfaces from no less than 98 per cent recycled glass and ceramic industrial waste. The initial products being made under the Block name are a range of small-to-medium sized occasional tables. Alusid is making the tabletops, while Collective HQ are making the bases. More details can be found here. Kickstarter awards "Project We Love" status to those which "really stand out".

 

The project shows the versatility of Alusid's patented processes to recycle industrial waste, much of which would otherwise go to landfill, to create attractive tiles, tabletops and other surfaces. Clients for bespoke products include Harrods, Selfridges, Amazon UK, Nando's and Pret-a-Manger, all of which have been secured by UK distributor Panaz.

 

Parkside Architectural Tiles, the commercial arm of Topps Tiles plc, is also distributing the Company's upmarket Sequel range of wall tiles.

 

Alusid has now also successfully adapted its patented technologies for scale up to mass production on industry-standard tile making equipment, increasing production capacity from 4,000m2 a year to 1,000m2 a day, opening up new markets for the Company. The initial production run has been bought by a major retailer.

 

Alusid is a spin out from the University of Central Lancashire ("UCLan"). It was co-founded by Chief Executive Officer Dr Alasdair Bremner and Creative Director Professor David Binns, who is also Head of Contemporary Ceramics at UCLan. Frontier IP holds a 35.6 per cent equity stake in Alusid.

 

Alusid co-founder and Chief Executive Officer, Dr Alasdair Bremner, said: "This Kickstarter project, in collaboration with Collective HQ, allows us to open up and demonstrate new creative possibilities for our material through these high-end tables. Our strong belief is people are keen to buy sustainable products, but only if they match the aesthetic appeal of non-sustainable equivalents. Block is an ideal way for us to show this."

 

Frontier IP Chief Executive Officer, Neil Crabb, said: "Alusid has made excellent progress this year, despite the uncertainty and delays caused by the COVID-19 outbreak. It has successfully demonstrated that it can scale up to mass production on industry-standard tile making equipment and has won new customers. This Kickstarter project and Block shows the Company can meet the needs of different markets across a number of different price points."

 

 

ENQUIRIES

 

Frontier IP Group Plc

T: 020 7332 2338

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

neil@frontierip.co.uk

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser)

T: 0203 328 5656

Nick Athanas / Nicholas Chambers

ABout frontier IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

About RNS Reach announcements

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAMZGGDNRRGGZM
Date   Source Headline
7th May 202410:15 amRNSTVG to collaborate with The Pirbright Institute
2nd May 20247:00 amRNSFrontier IP announces stake in DiaGen
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.